Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CBUS
CBUS logo

CBUS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.180
Open
3.980
VWAP
4.05
Vol
192.68K
Mkt Cap
267.88M
Low
3.970
Amount
779.71K
EV/EBITDA(TTM)
--
Total Shares
67.48M
EV
473.60M
EV/OCF(TTM)
--
P/S(TTM)
40.85
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Show More

Events Timeline

(ET)
2026-02-06
07:20:00
Cibus Joins UK Agriculture Innovation Project
select
2026-01-29 (ET)
2026-01-29
07:30:00
Cibus Prices Public Offering of 13.33 Million Shares at $1.50 Each
select
2026-01-28 (ET)
2026-01-28
16:10:00
Cibus Plans Underwritten Public Offering of Class A Common Stock
select
2026-01-05 (ET)
2026-01-05
07:20:00
Cibus and Interoc Sign LOI to Advance Herbicide-Tolerant Rice Commercialization
select
2025-12-11 (ET)
2025-12-11
07:10:00
Cibus Welcomes EU Agreement on New Genomic Techniques for Gene-Edited Plants
select
2025-11-13 (ET)
2025-11-13
16:29:07
Cibus Announces Q3 Earnings Per Share of 44 Cents, Exceeding Consensus Estimate of 18 Cents
select
2025-11-11 (ET)
2025-11-11
07:05:19
Cibus Appoints Wichner to Its Board of Directors
select
2025-10-16 (ET)
2025-10-16
07:50:37
Cibus and AgVaya Partner to Develop Solutions for Rice Farmers in India
select
2025-10-02 (ET)
2025-10-02
07:01:51
Cibus Finishes Field Trials for Second-Generation Herbicide-Tolerant Canola
select

News

Newsfilter
2.0
02-06Newsfilter
Cibus Develops Disease-Resistant Oilseed Varieties
  • Project Background: Cibus is participating as a key technology partner in a UK government-funded research project aimed at utilizing its proprietary Rapid Trait Development System™ (RTDS®) to combat Light Leaf Spot disease, which caused an estimated £300 million in yield losses in 2022, highlighting the project's significance for agricultural production.
  • Technology Application: By collaborating with the John Innes Centre and the University of Hertfordshire, Cibus applies its gene-editing expertise to develop new oilseed varieties, significantly shortening the time to market for new traits, thereby assisting farmers in tackling increasingly severe disease challenges and enhancing crop economic viability.
  • Partnership Composition: The project involves a consortium of 12 industry and academic partners aiming to deliver high-yielding oilseed varieties with durable multi-disease resistance by
Newsfilter
7.5
01-05Newsfilter
Cibus and Interoc Sign LOI for 2027 Market Entry in Latin America
  • Market Entry Plan: Cibus and Interoc have signed a non-binding Letter of Intent (LOI) to initiate commercialization in Ecuador and Colombia by 2027, followed by expansion into Peru, Central America, and the Caribbean, marking a significant shift from R&D to market execution in their collaboration.
  • Technology Integration: Cibus has successfully integrated herbicide-tolerant traits into Interoc's elite rice germplasm, which is expected to enhance productivity in Latin America by addressing urgent farmer needs against resistant weeds, thereby improving yields.
  • Collaboration Potential: The signing of the LOI establishes a framework for commercial sales, with Cibus and Interoc aiming to jointly promote high-performing rice hybrids in key markets, targeting rapid market share growth in rice production areas.
  • Sustainable Development Goals: By combining Cibus' gene-editing technologies with Interoc's elite genetics, both companies are committed to enhancing agricultural productivity and advancing sustainable farming practices in Latin America to meet the increasing food demand.
Globenewswire
7.5
2025-12-11Globenewswire
Cibus Advances Gene Editing Legislation in EU for Enhanced Plant Breeding
  • Legislative Progress: Cibus welcomes the agreement on the EU's New Genomic Techniques (NGTs) regulatory framework, marking a significant advancement in the company's efforts to innovate gene-edited plants, which is expected to provide European farmers with improved crop varieties.
  • Market Opportunities: This agreement offers Cibus legal assurance to develop new plant varieties in the European market, likely driving growth in the company's market share within the agricultural technology sector to meet increasing agricultural demands.
  • International Collaboration: Cibus has successfully completed field trials in the UK for its advanced trait in winter oilseed rape, demonstrating the company's leadership in gene editing technology and further enhancing its competitive edge in the European market.
  • Strategic Investment: Cibus's technology development aligns with the EU's legislative process, which is expected to create new growth opportunities for the company's product pipeline, particularly in addressing pressing agricultural challenges.
TipRanks
4.5
2025-11-25TipRanks
VTI ETF Daily Report—November 25, 2025
  • Vanguard Total Stock Market ETF Overview: The VTI ETF provides broad exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.

  • Market Performance: On Monday, VTI rose by 1.21%, while the Nasdaq Composite and S&P 500 increased by 2.7% and 1.5%, respectively, as investor confidence grew ahead of potential Federal Reserve policy easing.

  • Investment Trends: Despite a slight decline of 0.26% over the past five days, VTI is up 13% year-to-date, with a three-month average trading volume of 4.06 million shares and recent net inflows of $246 million.

  • Analyst Consensus and Potential: VTI is rated as a Moderate Buy with an average price target of $387.05, suggesting a 17.7% upside, while its Smart Score of seven indicates expected performance in line with the broader market.

TipRanks
4.5
2025-11-24TipRanks
Daily Update on VTI ETF – November 24, 2025
  • VTI Performance Overview: The Vanguard Total Stock Market ETF (VTI) is down 1.74% over the past week but has increased by 13% year-to-date, with a slight gain of 0.21% in pre-market trading on Monday.

  • Market Context: U.S. stocks, including the Nasdaq Composite and S&P 500, closed higher on Friday, recovering from a previous tech-led selloff, with VTI's trading volume averaging 4.06 million shares over three months.

  • Technical Analysis and Ratings: VTI has a Neutral rating overall but a Sell signal based on moving averages, currently trading at $323.80, below its 50-day moving average of $327.30.

  • Analyst Consensus and Holdings: VTI is rated as a Moderate Buy by analysts, with a price target of $392.91 suggesting a 21.3% upside, while it holds 3,488 stocks with varying potential for upside and downside.

TipRanks
4.5
2025-11-21TipRanks
VTI ETF Daily Report — November 21, 2025
  • VTI Overview: The Vanguard Total Stock Market ETF (VTI) provides extensive exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.

  • Recent Performance: VTI has experienced a 4.86% decline over the past week but is up 13.3% year-to-date, with notable declines in the Nasdaq Composite and S&P 500 due to market uncertainties.

  • Top Holdings: The ETF's leading holdings include Nvidia (6.69%), Microsoft (5.98%), and Apple (5.87%), with a three-month average trading volume of 4.02 million shares.

  • Analyst Consensus: VTI is rated as a Moderate Buy by analysts, with a price target suggesting a potential upside of 25%, while its Smart Score indicates it is likely to perform in line with the broader market.

Wall Street analysts forecast CBUS stock price to rise
3 Analyst Rating
Wall Street analysts forecast CBUS stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
15.00
Averages
18.67
High
25.00
Current: 0.000
sliders
Low
15.00
Averages
18.67
High
25.00
Canaccord
Austin Moeller
Buy
downgrade
$18
AI Analysis
2025-05-12
Reason
Canaccord
Austin Moeller
Price Target
$18
AI Analysis
2025-05-12
downgrade
Buy
Reason
Canaccord analyst Austin Moeller lowered the firm's price target on Cibus to $17.50 from $18 and keeps a Buy rating on the shares. The firm noted Cibus is not yet generating meaningful commercial revenues at this point in the company's lifecycle. However, through contract research on behalf of customers relating to collaborative agreements for products and traits, the company has consistently generated some quarterly revenue in advance of major trait commercializations. Cibus' nearest-term revenue-generation opportunity continues is its sustainable ingredients biofragrance product pipeline.
HC Wainwright & Co.
Amit Dayal
Strong Buy
Reiterates
$25
2025-03-21
Reason
HC Wainwright & Co.
Amit Dayal
Price Target
$25
2025-03-21
Reiterates
Strong Buy
Reason

Valuation Metrics

The current forward P/E ratio for Cibus Inc (CBUS.O) is -1.90, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess Cibus Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.79
Current PE
-1.90
Overvalued PE
-0.88
Undervalued PE
-4.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.71
Current EV/EBITDA
-7.47
Overvalued EV/EBITDA
-1.13
Undervalued EV/EBITDA
-6.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
58.16
Current PS
11.63
Overvalued PS
142.50
Undervalued PS
-26.17

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what are pre market low cap movers
Intellectia · 48 candidates
Market Cap: 30.00M - 3.00BRegion: USPrice: $0.30 - $30.00List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $100.00
Ticker
Name
Market Cap$
top bottom
IPSC logo
IPSC
Century Therapeutics Inc
459.90M
CBUS logo
CBUS
Cibus Inc
213.22M
GEOS logo
GEOS
Geospace Technologies Corp
130.55M
OBE logo
OBE
Obsidian Energy Ltd
573.46M
CGNT logo
CGNT
Cognyte Software Ltd
634.70M
VET logo
VET
Vermilion Energy Inc
1.73B
stocks that are up 15 % in last month
Intellectia · 406 candidates
List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: >= $15.00
Ticker
Name
Market Cap$
top bottom
ANL logo
ANL
Adlai Nortye Ltd
361.99M
NCI logo
NCI
Neo-Concept International Group Holdings Ltd
18.25M
LNKS logo
LNKS
Linkers Industries Ltd
16.66M
BATL logo
BATL
Battalion Oil Corp
67.97M
SGN logo
SGN
Signing Day Sports Inc
6.50M
MLEC logo
MLEC
Moolec Science SA
12.42M
top pick to buy today <$3
Intellectia · 34 candidates
Market Cap: >= 100.00MPrice: $0.50 - $3.00Moving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
ABOS logo
ABOS
Acumen Pharmaceuticals Inc
147.19M
CIG logo
CIG
Energy of Minas Gerais Co
6.16B
CRDL logo
CRDL
Cardiol Therapeutics Inc
112.24M
ROMA logo
ROMA
Roma Green Finance Ltd
119.13M
GORO logo
GORO
Gold Resource Corp
242.79M
ALTO logo
ALTO
Alto Ingredients Inc
199.16M
us stocks under 5$ marked to buy now
Intellectia · 85 candidates
Price: $0.50 - $5.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
CATX logo
CATX
Perspective Therapeutics Inc
281.74M
YCBD logo
YCBD
cbdMD Inc
10.92M
CNTX logo
CNTX
Context Therapeutics Inc
239.80M
ABOS logo
ABOS
Acumen Pharmaceuticals Inc
157.49M
ALLO logo
ALLO
Allogene Therapeutics Inc
413.50M
MNTK logo
MNTK
Montauk Renewables Inc
247.53M
most bullish ticker
Intellectia · 46 candidates
Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70
Ticker
Name
Market Cap$
top bottom
TARS logo
TARS
Tarsus Pharmaceuticals Inc
2.78B
DERM logo
DERM
Journey Medical Corp
276.86M
CYTK logo
CYTK
Cytokinetics Inc
7.93B
ABCL logo
ABCL
Abcellera Biologics Inc
1.19B
SVRA logo
SVRA
Savara Inc
1.16B
TSHA logo
TSHA
Taysha Gene Therapies Inc
1.29B

Whales Holding CBUS

B
BDT Capital Partners, LLC
Holding
CBUS
+0.18%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cibus Inc (CBUS) stock price today?

The current price of CBUS is 3.99 USD — it has increased 0.5

What is Cibus Inc (CBUS)'s business?

Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

What is the price predicton of CBUS Stock?

Wall Street analysts forecast CBUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBUS is18.67 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cibus Inc (CBUS)'s revenue for the last quarter?

Cibus Inc revenue for the last quarter amounts to 615.00K USD, decreased -63.11

What is Cibus Inc (CBUS)'s earnings per share (EPS) for the last quarter?

Cibus Inc. EPS for the last quarter amounts to -0.44 USD, decreased -94.23

How many employees does Cibus Inc (CBUS). have?

Cibus Inc (CBUS) has 157 emplpoyees as of March 11 2026.

What is Cibus Inc (CBUS) market cap?

Today CBUS has the market capitalization of 267.88M USD.